Question
Does a booster dose provide clinical benefit against symptomatic infection and serious illness due to COVID-19 in persons 60 years and older who are fully vaccinated with the Pfizer-BioNTech vaccine?
Conclusion
A booster (third) dose of the BNT162b2 mRNA vaccine from Pfizer-BioNTech provides significant additional protection against both infection and serious illness. (LOE = 2b)
Recent Posts
- How do ibuprofen, ketorolac, and diclofenac compare for the treatment of acute, nonradicular low back pain in adults?
- Are platelet-rich plasma injections effective for alleviating pain and improving function in adults with symptomatic ankle osteoarthritis?
- Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed
- Evidence of benefit is lacking for low back pain relief with muscle relaxants
- Fluvoxamine decreases hospitalizations in high-risk adults with COVID-19 (TOGETHER)